Faster global financial news!
AstraZeneca
-
Alnylam Pharmaceuticals' stock price has fallen by approximately 40% this year, but Wall Street analysts generally remain optimistic, with an average target price indicating about 50% upside potential.
Shares of biotechnology company Alnylam Pharmaceuticals (Nasdaq: ALNY) have fallen by approximately 40% year-to-date, but Wall Street analysts remain largely optimistic about its prospects. According
-
China's Akeso Says Its Cancer Drug Ivonescimab Outperformed AstraZeneca's Imfinzi in Phase 3 Trial for Biliary Tract Cancer
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug ivonescimab had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer.
-
AstraZeneca acquires global rights to lung cancer treatment Zegfrovy from Dizal Pharmaceutical for $600 million upfront, with potential for up to $1.5 billion
AstraZeneca will pay Dizal Pharmaceutical Co., Ltd. an initial $600 million, with an additional $900 million contingent on development, regulatory, and sales milestones. Zegfrovy (sunvozertinib) is an
-
A Wall Street Journal commentary noted that AstraZeneca shares are good value, whether a deal happens or not.
The Wall Street Journal commented that while the logic behind pharmaceutical giants' mergers and acquisitions is debatable, AstraZeneca's own performance record is not, considering its stock a bargain
-
AstraZeneca and Bristol-Myers Squibb are in merger talks; if the deal goes through, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion.
According to the British *Financial Times*, British pharmaceutical giant AstraZeneca and U.S. pharmaceutical company Bristol-Myers Squibb are engaged in advanced merger talks. If the deal is finalized
-
Alnylam Pharmaceuticals' stock price has fallen by approximately 40% this year, but Wall Street analysts generally remain optimistic, with an average target price indicating about 50% upside potential.
Shares of biotechnology company Alnylam Pharmaceuticals (Nasdaq: ALNY) have fallen by approximately 40% year-to-date, but Wall Street analysts remain largely optimistic about its prospects. According
-
China's Akeso Says Its Cancer Drug Ivonescimab Outperformed AstraZeneca's Imfinzi in Phase 3 Trial for Biliary Tract Cancer
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug ivonescimab had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer.
-
AstraZeneca acquires global rights to lung cancer treatment Zegfrovy from Dizal Pharmaceutical for $600 million upfront, with potential for up to $1.5 billion
AstraZeneca will pay Dizal Pharmaceutical Co., Ltd. an initial $600 million, with an additional $900 million contingent on development, regulatory, and sales milestones. Zegfrovy (sunvozertinib) is an
-
A Wall Street Journal commentary noted that AstraZeneca shares are good value, whether a deal happens or not.
The Wall Street Journal commented that while the logic behind pharmaceutical giants' mergers and acquisitions is debatable, AstraZeneca's own performance record is not, considering its stock a bargain
-
AstraZeneca and Bristol-Myers Squibb are in merger talks; if the deal goes through, it would create a pharmaceutical giant with a market capitalization of nearly $400 billion.
According to the British *Financial Times*, British pharmaceutical giant AstraZeneca and U.S. pharmaceutical company Bristol-Myers Squibb are engaged in advanced merger talks. If the deal is finalized
- No data
AstraZeneca
24H Trending
-
1
SK hynix in talks with Intel over potential US memory production agreement
-
2
Fetch.ai (FET) Token Analysis: Project Status and Investment Considerations
-
3
Bybit to adjust risk limits and leverage for selected perpetual contracts including 1000XECUSDT and BLASTUSDT, effective Sep 18, 2026
-
4
Anthropic, after calling for an AI slowdown, has signed its first data center lease in Australia, planning a total capacity of 2.16 GW.
-
5
Nikkei: Japan's MUFG Bank to Introduce Guidelines for Financing Defense Industry
-
6
Zhipu AI's CoWork business in China is progressing rapidly, with industry orders exceeding 1 billion yuan within one month of GLM-5.3's release.
-
7
Markets are cautiously optimistic ahead of the Federal Reserve's decision, with U.S. Treasuries slightly stronger, crude oil gains narrowing, and equity index futures holding steady.
-
8
Turkish Stocks Fall More Than 5% Amid Deepening Fund Redemption Woes
-
9
UK FCA Issues New Guidance for Crypto Assets, Preparing Firms for Authorization Applications Opening September 2026
-
10
FLWR Coin Status Analysis: Market Performance and Prospects of Two Tokens with the Same Name
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
